Work

AML-497 Salvage Treatment With Venetoclax (Ven) and Hypomethylating Agents (HMA) for Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (AML) Patients: Clinical Characteristics and Outcomes

Year: 2023

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(23)01070-4

Authors: Ahmad Ghorab, Mark Litzow, Naseema Gangat, Aref Al-Kali, Mithun Shah, Hemant Murthy, Hasan Alkhateeb, Kebede Begna, Mrinal Patnaik, James Foran, Talha Badar

Institutions: Mayo Clinic in Florida, Mayo Clinic

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4386282029

Cites:

Cited by:

Related to: 10